SCHEDULE: Biotechnology Value Fund Affiliates Hold 7.2% of ImageneBio
Beneficial Ownership Report (Schedule 13G Amendment)
Biotechnology Value Fund L.P. and its affiliates reported a 7.2% beneficial ownership stake in ImageneBio, Inc. common stock as of September 30, 2025.
Summary
- Biotechnology Value Fund L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership of ImageneBio, Inc. common stock.
- As of September 30, 2025, the aggregate beneficial ownership by BVF Partners L.P., BVF Inc., and Mark N. Lampert amounted to 802,102 shares.
- This aggregate ownership represents approximately 7.2% of ImageneBio, Inc.'s outstanding common stock.
- The percentage is based on 11,181,676 shares outstanding as of July 25, 2025, as disclosed in ImageneBio's Form S-1 registration statement.
- Individual entities within the group hold varying percentages: BVF holds 3.7% (415,765 shares), BVF2 holds 2.9% (325,596 shares), and Biotechnology Value Trading Fund OS LP holds 0.4% (44,578 shares).
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the disclosure of a significant institutional ownership stake by a specialized biotechnology fund, which implies investor confidence. However, the filing itself does not provide operational or financial performance data.
Positives
- Significant institutional ownership by a specialized biotechnology investment fund (Biotechnology Value Fund L.P. and its affiliates) signals a notable level of confidence in ImageneBio, Inc.'s long-term potential.
- The substantial stake of 7.2% indicates a strong commitment from a sophisticated investor group in the company's future.
Risks
- The filing itself does not detail specific risks related to ImageneBio, Inc.'s operations or financial health, as it is a beneficial ownership report.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding ImageneBio, Inc.'s future performance or strategic direction, as it is solely a beneficial ownership disclosure.
Industry Context
The disclosure of a significant stake by a dedicated biotechnology investment fund like Biotechnology Value Fund L.P. suggests that ImageneBio, Inc. is on the radar of specialized institutional investors. This can be a positive indicator within the competitive biotechnology sector, where investor confidence often hinges on perceived innovation, pipeline strength, and market potential.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by a specialized fund may be viewed positively, potentially increasing investor confidence and market interest in ImageneBio, Inc.'s stock.
- Company Management: A substantial institutional investor may exert influence on corporate governance or strategic decisions, aligning with long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 2025-07-25 | Date on which ImageneBio, Inc.'s 11,181,676 shares outstanding were reported in its Form S-1. |
| 2025-09-08 | Date ImageneBio, Inc. filed its Registration Statement on Form S-1 with the SEC. |
| 2025-09-30 | Date of event which requires the filing of this Schedule 13G amendment, reflecting the beneficial ownership. |
| 2025-11-14 | Date the Schedule 13G Amendment No. 5 was signed and filed by the Reporting Persons. |
Keywords
ImageneBio, Biotechnology Value Fund, BVF, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Common Stock, Equity Stake, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.